BTL Industries Inc (BTL), manufacturer of the EMSCULPT body-contouring device and other products for non-invasive body-shaping procedures, has filed a complaint with the United States International Trade Commission (ITC), asking the Commission to prevent Allergan Limited, Allergan Inc, Allergan USA Inc, Zeltiq Aesthetics Inc, Zeltiq Ireland Unlimited Company (Allergan), and Zimmer MedizinSysteme GmbH, Germany (Zimmer) from importing products that infringe BTL’s patents into the United States.
BTL concurrently filed a lawsuit with the US Federal District Court in the District of Delaware against Allergan and Zimmer on the same matter.
The US International Trade Commission is an independent, quasi-judicial federal agency with broad investigative responsibilities on matters that affect trade and commerce, including intellectual property infringement.
“We have asked the ITC to determine whether CoolTone and CoolSculpting products infringe BTL’s patents and, if they are found to be infringing, to issue an exclusion order barring importation of CoolTone and CoolSculpting products into the US, as well as issuing a cease-and-desist order prohibiting Allergan and Zimmer from selling their infringing products and their components in the American market space.”
— Ron Borsheim, VP of Business Development, BTL
BTL’s ITC complaint and Delaware lawsuit follows a lawsuit that BTL filed with the US. District Court in Delaware in December 2019 on similar matters.
[Source(s): BTL, PR Newswire]
Related Content:
BTL Continues to Transform Non-Invasive Aesthetics by Launching the EMSELLA Applicator with Up to 2.5 Tesla for the EMSCULPT Platform
MedShift and BTL Aesthetics Enter Strategic Partnership for Emsculpt Device
BTL Presents EMSCULPT Research at ASLMS Meeting
